An Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
March 2012 | Volume 11 | Issue 3 | Original Article | 300 | Copyright © March 2012
Kristian Reich MD,a Kim A. Papp MD,b Christopher E. M. Griffiths MD,c Philippe O. Szapary MD,d Newman Yeilding MD,d Yasmine Wasfi MD,d Elyssa Ott MPH,d Ming-Chun Hsu PhD,d Mark Lebwohl MD,e Kenneth B. Gordon MD,f on behalf of the PHOENIX 1, PHOENIX 2, and ACCEPT investigators
aDermatologikum Hamburg, Hamburg, Germany bProbity Medical Research, Waterloo, Ontario, Canada cUniversity of Manchester, Manchester Academic Health Science Centre, Manchester, UK dJanssen Research & Development, LLC, Spring House, PA eMount Sinai Medical Center, New York, NY fNorthwestern University, Feinberg School of Medicine, Chicago, IL
You will have 48 hours to download the full-text PDF
